Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Operating Income (2016 - 2025)

Historic Operating Income for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to -$189000.0.

  • Fennec Pharmaceuticals' Operating Income rose 9636.68% to -$189000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year decrease of 37690.02%. This contributed to the annual value of $2.6 million for FY2024, which is 12010.81% up from last year.
  • Fennec Pharmaceuticals' Operating Income amounted to -$189000.0 in Q3 2025, which was up 9636.68% from -$2.7 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Operating Income peaked at $13.7 million during Q1 2024, and registered a low of -$9.6 million during Q4 2022.
  • Moreover, its 5-year median value for Operating Income was -$4.0 million (2021), whereas its average is -$2.9 million.
  • Data for Fennec Pharmaceuticals' Operating Income shows a peak YoY increase of 36077.8% (in 2024) and a maximum YoY decrease of 41150.44% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Operating Income stood at -$4.2 million in 2021, then plummeted by 129.4% to -$9.6 million in 2022, then soared by 81.01% to -$1.8 million in 2023, then soared by 48.62% to -$934000.0 in 2024, then skyrocketed by 79.76% to -$189000.0 in 2025.
  • Its Operating Income stands at -$189000.0 for Q3 2025, versus -$2.7 million for Q2 2025 and -$808000.0 for Q1 2025.